Management of Crohn's disease in adults

American Journal of Gastroenterology

Volumn 92, Issue 4, 1997, Pages 559-566

  Hanauer, Stephen B ^a,c   Meyers, Samuel ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE;

ANTIBIOTIC THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; HUMAN; INTESTINE RESECTION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0030896836     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Feagan BG, McDonald JW, Koval JJ. Therapeutics and inflammatory bowel disease: A guide to the interpretation of randomized controlled trials. Gastroenterology 1996;110:275-83.
2. Rubin PH, Present DH. Differential diagnosis of chronic ulcerative colitis in Crohn's disease of the colon. In: Kirsner JB, Shorter RG, eds. Inflammatory Bowel Disease, 4th ed. Baltimore: Williams & Wilkins, 1995, pp 355-79.
3. Kirschner BS. Ulcerative colitis and Crohn's disease in children. Gastroenterol Clin North Am 1995;24:99-107.
4. Linssen A, Tygat GN. Fulminant onset of Crohn's disease of the colon (CDC): An observation of six cases. Dig Dis Sci 1982;27: 731-6.
5. Farmer RG, Hawk WA, Tumbull RB. Clinical patterns in Crohn's disease: A statistical study of 615 cases. Gastroenterology 1975;68: 627-35.
6. Sachar DB, Andrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterol Int 1992;5: 141-54.
7. Mekhjian HS, Switz DM, Meinyk CS, et al. Clinical features and natural history of Crohn's disease. Gastroenterology 1979;77:898-906.
8. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease: Relationship between the clinical pattern and prognosis. Gastroenterology 1985;88:1818-25.
9. Agha FP, Ghahremani GG, Panella JS, et al. Appendicitis as the initial manifestation of Crohn's disease: Radiologic features and prognosis. Am J Roentgenol 1987;149:515-8.
10. Lindhagen T, Ekelund, Leandoer L, et al. Crohn's disease confined to the appendix. Dis Colon Rectum 1982;25:805-8.
11. Ogorek CP, Fisher RS. Differentiation between Crohn's disease and ulcerative colitis. Med Clin North Am 1994;78:1249-58.
12. Greenstein AJ, Janowitz HD, Sachar DB. The extraintestinal complications of Crohn's disease and ulcerative colitis: A study of 700 patients. Medicine 1976;55:401-12.
13. Williams NS, Made J, Celestin R. Anorectal Crohn's disease. Br J Surg 1979;66:743-8.
14. Tan WC, Allan RN. Diffuse jejunoileitis of Crohn's disease. Gut 1993;34:1374-8.
15. Nugent FW, Roy MA. Duodenal Crohn's disease: An analysis of 89 cases. Am J Gastroenterol 1989;84:249-54.
16. Griffiths AM, Alemayehu E, Sherman P. Clinical features of gastroduodenal Crohn's disease in adolescents. J Pediatr Gastroenterol Nutr 1989;8:166-71.
17. Cray ER, Tremaine WJ, Banks PM, et al. Isolated Crohn's disease of the stomach. Mayo Clin Proc 1989;64:776-9.
18. Schumacher G, Sandstedt B, Kollberg B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis: Clinical findings and early diagnosis. Scand J Gastroenterol 1994;29:265-74.
19. Hodgson HJF, Mazlam MZ. Review article: Assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Ther 1991;5:555-84.
20. Waye JD. Endoscopy in inflammatory bowel disease. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins, 1995, pp 555-82.
21. Anonymous. The role of colonoscopy in patients with inflammatory bowel disease guidelines for clinical application. Gastrointest Endosc 1988;34(suppl3):10S-1S.
22. Modigliani R, Mary Y-J, Simon JF, et al. (Group d'etude therapeutiques des affections inflammatoires digestives clinical biological and endoscopie picture of attacks of Crohn's disease: Evolution on prednisolone. Gastroenterology 1990;98:811-8.
23. Rutgeerts P, Ggeboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99: 956-63.
24. Riddell RH. Pathology of idiopathic inflammatory bowel disease. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins, 1995, pp 517-52.
25. Mee AS, Jewel DP. Factors inducing relapse in inflammatory bowel disease. Br Med J 1978;2:801-2.
26. Trnka YM, LaMont JT, Peppercorn MA. Association of C. difficile toxin with relapse of chronic inflammatory bowel disease. Gastroenterology 1981;80:693-6.
27. Meyers S, Mayer L, Bottone E, et al. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 1981;80:697-700.
28. Silverstein MD, Lashner BA, Hanauer SB, et al. Cigarette smoking in Crohn's disease. Am J Gastroenterol 1989;84:31-3.
29. Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98:1123-8.
30. Kaufman HJ, Taubin HL. Non-steroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987;107:513-6.
31. Bjarnason I, Hayllar J, MacPherson A, et al. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-47.
32. Kaplan MA, Korelitz BI. Narcotic dependence in inflammatory bowel disease. J Clin Gastroenterol 1988;10:275-8.
33. Ramchandani D, Schindler B, Katz J. Evolving concepts of psychopathology in inflammatory bowel disease. Med Clin North Am 1994; 78:1321-30.
34. North CS, Alpers DH, Heizer JE, et al. Do life events or depression exacerbate inflammatory bowel disease. Ann Intern Med 1991;114: 381-6.
35. Hanauer SB. Measures of disease activity. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: From bench to bedside. Baltimore: Williams & Wilkins, 1994, pp 429-44.
36. Kjeldsen J. Assessment of disease severity and activity in inflammatory bowel disease. Scand J Gastroenterol 1993;28:1-9.
37. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis. Ann Intern Med 1995; 122:132-42.
38. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47.
39. Beck IT. Laboratory assessment of inflammatory bowel disease. Dig Dis Sci 1987;32:26S-41S.
40. Group D'Etudes Therapeutiques Des Affections Inflammatories Du Tube Digestif (GETAID) Presented by JY Mary and R Modigliani. Development and validation of an endoscopie index of the severity for Crohn's disease: A prospective multicentre study. Gut 1989;30: 983-9.
41. Irvine EJ (for the McMaster IBD Study Group). Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. J Clin Gastroenterol 1995;20:27-32.
42. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994;106:287-96.
43. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: Results of drug treatment. Gastroenterology 1979;77:847-69.
44. Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDES): Results of drug treatment. Gastroenterology 1984;86:249-66.
45. Anthonisen P, Barany F, Folkenborg O, et al. The clinical effect of salzosulphapyridine (Salazopyrin) in Crohn's disease. Scand J Gastroenterol 1974;9:549-54.
46. Van Hess PAM, Van Lier HJJ, Van Elteren PH, et al. Effect of sulphasalazine in patients with active Crohn's disease: A controlled double-blind study. Gut 1981;22:404-9.
47. Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Gastroenterology 1993;104:1293-1301.
48. Salomon P, Kornbluth A, Aisenberg J, et al. How effective are current drugs for Crohn's disease? A meta-analysis. J Clin Gastroenterol 1992;14:211-5.
49. Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991;32: 1071-5.
50. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The Cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology 1982; 83:550-62.
51. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993;17:235-7.
52. Prantera C, Kohn A, Zannoni F, et al. Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: Results of an open study. J Clin Gastroenterol 1994;19:79-80.
53. Valori RM, Cockel R. Omeprazole for duodenal ulceration in Crohn's disease. Br Med J 1990;300:438-9.
54. Dickinson JB. Is omeprazole helpful in inflammatory bowel disease? J Clin Gastroenterol 1994;18:317-9.
55. Korelitz BI, Adler DJ, Mendelsohn RA, et al. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am J Gastroenterol 1993;88:1198-1205.
56. Meyers S, Sachar DB. Medical therapy of Crohn's disease. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins, 1995, pp 695-714.
57. Rijk MCM, Van Hogezand RA Van Lier HJJ, et al. Sulphasalazine and prednisone compared with sulphasalazine for treating active Crohn's disease. Ann Intern Med 1991;114:445-50.
58. Munkholm P, Langholz E, Davidsen M, et al. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35: 360-2.
59. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: A long term randomized double blind study. N Engl J Med 1980;302:981-7.
60. Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 1993;34:1198-202.
61. Sanderson IR, Udeen S, Davies PSW, et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987; 61:123-7.
62. Raouf AH, Hildrey V, Daniel J, et al. Enteral feeding as sole treatment for Crohn's disease: Controlled trial of whole protein versus amino acid based feed and a case study of dietary challenge. Gut 1991;32:702-7.
63. Rigaud D, Cosnes J, Le Quintrec Y, et al. Controlled trial comparing two types of enterai nutrition in treatment of active Crohn's disease: Elemental versus polymeric diet. Gut 1991;32:1492-7.
64. Gonzalez-Huix F, de Leon R, Femandez-Banares F, et al. Polymeric enterai diets as primary treatment of active Crohn's disease: A prospective steroid controlled trial. Gut 1993;34:778-82.
65. Griffiths AM, Ohlsson A, Sherman PM, et al. Meta-analysis of enterai nutrition as a primary treatment of active Crohn's disease. Gastroenterology 1995;108:1056-67.
66. Lochs H, Steinhardt HJ, Klaus-Wentz B, et al. Comparison of enteral nutrition and drug treatment in active Crohn's disease: Results of the European Cooperative Crohn's Disease Study IV. Gastroenterology 1991;101:881-8.
67. Shepard HA, Barr GD, Jewell DP. Use of an intravenous steroid regimen in the treatment of acute Crohn's disease. J Clin Gastroenterol 1986;8:154-9.
68. Ostro MJ, Greenberg GR, Jeejeebhoy KN. Total parenteral nutrition and complete bowel rest in the management of Crohn's disease. J Parenter Enterai Nutr 1985;9:280-7.
69. Greenberg GR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988;29:1309-15.
70. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology 1980;79:357-65.
71. Solomon MJ, McLeod RS, O'Connor BI, et al. Combination ciprofloxacin and metronidazole in severe perianal Crohn's disease. Can J Gastroenterol 1993;7:571-3.
72. Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: A follow-up study. Gastroenterology 1982; 83:383-7.
73. Duffy LF, Daum F, Fisher SE, et al. Peripheral neuropathy in Crohn's disease patients treated with metronidazole. Gastroenterology 1985; 88:681-4.
74. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistula with continuous intravenous cyclosporine A. Am J Gastroenterol 1993;88: 646-9.
75. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994;39:374-80.
76. Smith RC, Rhodes J, Heatley RV, et al. Low dose steroids and clinical relapse in Crohn's disease: A controlled trial. Gut 1978;19:606-10.
77. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study. Gastroenterology 1996;110:45-51.
78. Bayless TM. Maintenance therapy for Crohn's disease. Gastroenterology 1996;110:299-301 (editorial).
79. Sachar DB. Maintenance therapy in ulcerative colitis and Crohn's disease. J Clin Gastroenterol 1995;20:117-22.
80. Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: A controlled evaluation. Gastroenterology 1974; 66:916-22.
81. Rosenberg JL, Leven B, Wall AJ, et al. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975;20:721-6.
82. Rhodes J, Bainton D, Beck P, et al. Controlled trial of azathioprine in Crohn's disease. Lancet 1971;2:1273-6.
83. Ewe K, Presse AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
84. Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994;89:362-6.
85. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
86. Bernstein CN, Artinian L, Anton PA, et al. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci 1994;39:1638-41.
87. Hanauer SB, Meyers S, Sachar DB. The pharmacology of anti-inflammatory drugs in inflammatory bowel disease. In. Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins, 1995, pp 643-63
88. Present DH, Meltzer SJ, Krumholz MP, et al. 6-mercaptopurine in the management of inflammatory bowel disease: Short and long term toxicity. Ann Intern Med 1989;111:641-9.
89. Feagan BG, Rochon J, Fedorak RN, et al. for the North American Crohn's Study Group Investigators. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
90. Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994;330:1846-51.
91. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporine in chronic active Crohn's disease: A 12-month study. The European Study Group. Gastroenterology 1995;109:774-82.
92. Ewe K, Herfarth C, Makhow H, et al. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: A multicenter trial. Digestion 1989;42:224-32.
93. Steinhart HA, Hemphill D, Greenberg R. Sulfasalazine and mesalazine for maintenance therapy of Crohn's disease: A meta-analysis. Am J Gastroenterol 1994;89:211-24.
94. Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: A meta-analysis. Am J Gastroenterol 1994;89:692-8.
95. Gendre JP, Mary JY, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. The Groupe d Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Gastroenterology 1993;104: 435-9.
96. Caprilli R, Anreoli A, Capurso L, et al. 5-ASA in the prevention of Crohn's disease postoperative recurrence: An interim report of the Italian Study Group of the Colon (CISC). Aliment Pharmacol Ther 1994;8:35-43.
97. Modigliani R, Colombel JF, Dupas L, et al. Mesalamine in Crohn's disease with steroid-induced remission: Effect on steroid withdrawal and remission maintenance. Gastroenterol 1996;110:688-93.
98. Brignola C, Cottone M, Fera A, et al. Mesalamine in the prevention of endoscopie recurrence after intestinal resection for Crohn's disease. Gastroenterology 1994;108:345-9.
99. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72.
100. Fazio VW, Strong SA. The surgical management of Crohn's disease. In: Kirsner JB, Shorter RG, eds. Inflammatory bowel disease, 4th ed. Baltimore: Williams & Wilkins 1995, pp 830-87.
101. Meyers S, Walfish JS, Sachar DB, et al. Quality of life after surgery for Crohn's disease: A psychosocial survey. Gastroenterology 1980; 78:1-6.
102. Greenberg GR, Feagan BG, Martin F, et al (and the Canadian Inflammatory Bowel Disease Study Group). Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41.
103. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842-5.
104. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
105. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.